China Market · Cross-Border Healthcare
The addressable market, buyer segments, geographic entry points, regulatory landscape, and competitive position.
Fortune 500 and Chinese state enterprise HR departments managing employees on international assignment. The employer is the buyer — individual employee consent is assumed within the corporate health benefit. Annual contract. Predictable revenue. No case-by-case sales process.
High-net-worth patients in Beijing, Shanghai, and Shenzhen. Self-pay. Price-insensitive when health is at stake — these are individuals who travel business class to a $40,000 surgical procedure. The synthesis fee is a rounding error in their total spend.
JCI-accredited hospitals in China, international clinic chains, specialist referral centers. White-label deployment with per-case volume fee on top of annual license.
Agencies organizing international patient travel to US and European hospitals. Currently handling record translation manually. Platform replaces their manual process entirely.
International health insurance products sold to Chinese nationals. Underwriting requires standardized health records. Claims processing requires verified longitudinal history.
Three-city China entry concentrates the addressable market. Hong Kong as the data bridge. Southeast Asia and Europe as expansion in Year 2.
National institutions, diplomatic community, government officials, state enterprise HQ. Strongest concentration of patients with both the need and the means for international specialist care.
Financial center. Largest expatriate population in China. Most internationalized healthcare market. Multiple JCI-accredited hospitals. Primary corporate health contract concentration.
Tech industry concentration. High-income young professional demographic. Border proximity to Hong Kong international medical infrastructure. Growing private healthcare market.
Bridge between mainland PIPL data environment and international healthcare. Established Western medical infrastructure. Regional operations center. Less restrictive data environment for cross-border processing.
Singapore, Bangkok, Kuala Lumpur. Large Chinese expatriate populations. Existing medical tourism infrastructure. Platform standardizes cross-border referral from all three cities to US and European specialists.
London, Zurich, Munich. Chinese patients seeking European specialist care face the identical data wall. Platform output formatted for European specialist requirements alongside US institutions.
The Medical Data Wall exists in every country. Indian patients seeking US care. African patients seeking European care. Latin American patients. The architecture is universal. The China market is the entry point, not the ceiling.
Two jurisdictions, two regulatory frameworks. Both designed into the architecture from the start — not retrofitted.
Five comparisons. In each case the platform occupies a position that existing options do not reach.
Translation services produce PDFs that specialists still reject. The platform produces structured data in the specialist's required format — not a translation, a data transformation. The end product is different in kind, not just quality.
EHR vendors solve record storage for institutions. They have no Chinese language capability, no TCM schema, no cross-border intake pipeline. They are a source of output data for the platform, not a competitor. The platform processes their FHIR exports.
Chinese apps store records within China. They have no Western specialist output pipeline and no TCM-Western integration layer. They are a data source for the platform — ingestion adapters connect directly to their export formats.
Agencies handle logistics — flights, hotels, appointment scheduling. They do not process records. They are a distribution channel. The platform replaces their manual record handling and makes them more competitive with their own clients.
Consumer AI cannot handle PHI at scale, produces no verifiable provenance, cannot be deployed under PIPL or HIPAA, and has no TCM schema. Not a competitive threat — it is a positioning differentiator. The platform is what consumer AI cannot be.